Table III.

Characteristics of patients with relapsed/refractory AML (cohort 2).

Total number of patients	n = 102
Median age (years, range)	66 (21–88)
M/F (%)	52/48
Median no. of prior therapies (range)	2 (1–5)
Prior anthracycline/ara-C induction (%)	57
Prior low-intensity induction (%)	39
Decitabine single-agent salvage (%)	59
Decitabine + GO salvage (%)	41
ECOG performance status (%)
0	25
1	49
2	19
3	7
Unknown	1
Cytogenetics (%)
Adverse	30
Intermediate	70
Baseline bilirubin (%)
≤ 1.3	92
> 1.3	8
Baseline creatinine (%)
≤ 1.3	81
> 1.3	19
CR	16 (15.7%)
NR	86 (84.3%)

AML, acute myeloid leukemia; M/F, male/female; GO, gemtuzumab ozogamicin; ECOG, Eastern Cooperative Oncology Group; CR, complete response; NR, no response.